| Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases (NCT06537297) | Hunan Province Tumor Hospital | 2024-09-30 |
| Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma (NCT06574126) | PETHEMA Foundation | 2024-09-30 |
| Fisetin to Reduce Senescence and Mobility Impairment in PAD (NCT06399809) | Northwestern University | 2024-09-30 |
| A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients. (NCT04469127) | Advanced Imaging Projects, LLC | 2024-09-30 |
| BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma (NCT06588335) | Henan Provincial People's Hospital | 2024-09-30 |
| Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab (NCT06516289) | Fudan University | 2024-09-30 |
| Study of Stapokibart Injection in Patients With Allergic Rhinitis (NCT06525597) | Keymed Biosciences Co.Ltd | 2024-09-30 |
| The Use of Melatonin for Delirium Prevention in Medically Hospitalized Patients (NCT06509191) | Sultan Qaboos University | 2024-09-30 |
| Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease (NCT06482437) | NMD Pharma A/S | 2024-09-30 |
| The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer (NCT06592287) | Xianglin Yuan | 2024-09-30 |
| Allopurinol Improves Heart Function in African Americans With Resistant Hypertension (NCT05888233) | VA Office of Research and Development | 2024-09-30 |
| tDCS for Post-Stroke Cognitive Impairment (NCT06516588) | University of Oklahoma | 2024-09-30 |
| A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body (NCT06421636) | Regeneron Pharmaceuticals | 2024-09-30 |
| A Phase 2 Study of HB0017 in Psoriasis Patients (NCT06592274) | Huabo Biopharm Co., Ltd. | 2024-09-30 |
| ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd (NCT06578286) | Fudan University | 2024-09-30 |
| Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer (NCT06361940) | Medical College of Wisconsin | 2024-09-30 |
| Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule (NCT06620354) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2024-09-30 |
| Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma (NCT06242834) | Northwestern University | 2024-09-30 |
| Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial (NCT06620822) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-09-30 |
| GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC (NCT06611826) | Zhejiang Cancer Hospital | 2024-09-30 |
| Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma (NCT06609239) | Sanofi | 2024-09-30 |
| A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease (NCT06602258) | Eisai Inc. | 2024-09-30 |
| Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients (NCT06657859) | Glycomine, Inc. | 2024-09-30 |
| Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer (NCT06493019) | Dustin Deming | 2024-09-30 |
| Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma (NCT06447636) | Fudan University | 2024-09-30 |
| Individualized Intraoperative PEEP Following Alveolar Recruitment Maneuvres and Postoperative Respiratory Complications (NCT06600386) | Asklepieion Voulas General Hospital | 2024-09-30 |
| A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer (NCT06620796) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-09-30 |
| Evaluation of Intravenous Sodium Valproate on Interleukin-6 Levels in Patients With TMJ Disc Displacement (NCT07487675) | Tanta University | 2024-09-29 |
| Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer (NCT05613452) | Shanghai Proton and Heavy Ion Center | 2024-09-29 |
| Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML (NCT06635681) | Institute of Hematology & Blood Diseases Hospital, China | 2024-09-29 |
| Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer (NCT06530303) | Essen Biotech | 2024-09-29 |
| --SuPERIOR Trial-- (NCT06191250) | University Health Network, Toronto | 2024-09-28 |
| A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease (NCT06613698) | GlaxoSmithKline | 2024-09-27 |
| Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists (NCT06640972) | Response Pharmaceuticals | 2024-09-27 |
| First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors (NCT06622486) | Egle Therapeutics | 2024-09-27 |
| Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) (NCT06317649) | National Cancer Institute (NCI) | 2024-09-27 |
| Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial (NCT06184750) | National Cancer Institute (NCI) | 2024-09-27 |
| Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma (NCT06194656) | Shanghai Institute Of Biological Products | 2024-09-27 |
| Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19 (NCT05212662) | Thiogenesis Therapeutics, Inc. | 2024-09-27 |
| A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma (NCT06564272) | Beijing Konruns Pharmaceutical Co., Ltd. | 2024-09-27 |
| A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT06589778) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2024-09-27 |
| Skin Care Regimen for Improving Photoaging Signs on the Face (NCT06603857) | Goldman, Butterwick, Fitzpatrick and Groff | 2024-09-27 |
| Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy (NCT06634108) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2024-09-27 |
| JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases (NCT06586866) | JenKem Technology Co., Ltd. | 2024-09-26 |
| High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients (NCT05947071) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-09-26 |
| A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL) (NCT06594679) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2024-09-26 |
| Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (NCT06463665) | Genelux Corporation | 2024-09-26 |
| A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer (NCT06755515) | Shandong New Time Pharmaceutical Co., LTD | 2024-09-26 |
| Lamivudine for Solid Tumors (NCT06494579) | Thomas Marron | 2024-09-26 |
| Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects (NCT06621017) | Rose Pharma Inc | 2024-09-26 |
| Study of YK012 in B-cell Acute Lymphoblastic Leukemia (NCT06580301) | Excyte Biopharma Ltd | 2024-09-25 |
| A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer (NCT06315491) | Cybrexa Therapeutics | 2024-09-25 |
| KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome (NCT06588491) | Kyverna Therapeutics | 2024-09-25 |
| Combination Therapy for Recurrent Ovarian Cancer (NCT05610735) | Sham Sunder Kakar | 2024-09-25 |
| A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH) (NCT06462235) | Pfizer | 2024-09-25 |
| ALPINE: Maintenance Letrozole/Abemaciclib (NCT06366347) | Dana-Farber Cancer Institute | 2024-09-25 |
| Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) (NCT05554406) | National Cancer Institute (NCI) | 2024-09-25 |
| Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment (NCT06563245) | Children's Cancer Group, China | 2024-09-25 |
| Lemborexant for the Treatment of Residual Insomnia in Major Depressive Disorder (MDD) (NCT06843187) | Unity Health Toronto | 2024-09-25 |
| A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC (NCT06597565) | H. Lee Moffitt Cancer Center and Research Institute | 2024-09-25 |
| Study of 18F-FFNP Breast PET/MRI (NCT06086704) | University of Wisconsin, Madison | 2024-09-25 |
| A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer (NCT06568094) | Jiangsu HengRui Medicine Co., Ltd. | 2024-09-25 |
| A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) (NCT06530251) | Akeso | 2024-09-24 |
| Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma (NCT06581640) | The First Affiliated Hospital of Xiamen University | 2024-09-24 |
| Epcoritamab-CAR T Cells for Large B-cell Lymphomas (NCT06458439) | Abramson Cancer Center at Penn Medicine | 2024-09-24 |
| Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough (NCT06504446) | Nocion Therapeutics | 2024-09-24 |
| Preventing Medication Mismanagement in People Living with Dementia Through Automated Medication Dispensing with Facial Recognition and Video Observation (NCT06691256) | HiDO Technologies | 2024-09-24 |
| Pola-ZR2P in Previously Untreated DLBCL (NCT06664411) | Navy General Hospital, Beijing | 2024-09-24 |
| A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA) (NCT06606847) | AstraZeneca | 2024-09-24 |
| Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer (NCT06391034) | Robert Bok, MD, PhD | 2024-09-24 |
| ChemoRT With and Without Dental Stent for Taste Protection in NPC Patients (NCT06733948) | National University Hospital, Singapore | 2024-09-24 |
| Lymphedema Prevention Through Immediate Lymphatic Reconstruction (LILY) Trial. (NCT06989099) | M.D. Anderson Cancer Center | 2024-09-24 |
| Trial of THEO-260 in Ovarian Cancer Patients (NCT06618235) | Theolytics Limited | 2024-09-24 |
| Evaluating the Accuracy of Soft Tissue Prediction in Patients With Mandibular Prognathism After Orthognathic Surgery Using Handheld Scanner Versus Optical Scanner A Prospective Clinical Trial (NCT06724497) | Cairo University | 2024-09-24 |
| RC48 in Combination With AK104 and Bevacizumab in OCCC (NCT06540729) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2024-09-24 |
| Serotonin Control of Impulsivity in Tourette Disorder (NCT05942716) | Hospices Civils de Lyon | 2024-09-24 |
| A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC (NCT06775275) | The First Affiliated Hospital of Guangzhou Medical University | 2024-09-24 |
| RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure (NCT06663007) | Tianjin Medical University Second Hospital | 2024-09-24 |
| A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (NCT06681922) | Northwell Health | 2024-09-23 |
| Regorafenib for Recurrent Meningioma (MIRAGE Trial) (NCT06275919) | Istituto Oncologico Veneto IRCCS | 2024-09-23 |
| Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism (NCT06246357) | National Cancer Institute (NCI) | 2024-09-23 |
| Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor (NCT05933395) | Dartmouth-Hitchcock Medical Center | 2024-09-23 |
| Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia (NCT06574360) | China Medical University Hospital | 2024-09-23 |
| Orthobiologic Treatment for Knee Osteoarthritis (NCT06893250) | University Hospital of North Norway | 2024-09-23 |
| Psilocybin in Cancer Pain Study (NCT06001749) | Yvan Beaussant, MD, MSci | 2024-09-23 |
| A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight (NCT06606483) | MindRank AI Ltd | 2024-09-23 |
| Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP) (NCT06441747) | Australasian Gastro-Intestinal Trials Group | 2024-09-23 |
| Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation (NCT06529731) | Sawa Ito, MD | 2024-09-23 |
| Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) (NCT06384560) | Amsterdam UMC, location VUmc | 2024-09-23 |
| A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (NCT06284486) | M.D. Anderson Cancer Center | 2024-09-23 |
| A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body (NCT06413680) | Regeneron Pharmaceuticals | 2024-09-23 |
| Impact of Two Occlusal Schemes in Implant Retained Mandibular Overdenture on the Masticatory Efficiency (NCT06784050) | Ain Shams University | 2024-09-22 |
| A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT (NCT05171894) | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 2024-09-21 |
| Target-specific immunoPET Imaging of Breast Cancer (NCT06715826) | RenJi Hospital | 2024-09-21 |
| Combination of TURP and Standard Systemic Therapy for MPCa (NCT06655259) | Fudan University | 2024-09-21 |
| A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC) (NCT06299111) | Regeneron Pharmaceuticals | 2024-09-20 |
| A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes (NCT06603571) | Eli Lilly and Company | 2024-09-20 |
| A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors (NCT06598007) | Crossignal Therapeutics, Inc. | 2024-09-20 |
| Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC (NCT06599827) | Shanghai Zhongshan Hospital | 2024-09-20 |
| Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE (NCT06607276) | The First Affiliated Hospital with Nanjing Medical University | 2024-09-20 |